Yüksel Ürün: Lack of Synergy Between AR-Targeted Therapies and PARP Inhibitors

Yüksel Ürün, Medical Oncology Professor at Ankara University School of Medicine, shared a post on X:

“Combination of AR – targeted therapy and PARP inhibitors shows no synergy in HR – proficient prostate cancer. Contrary to earlier models, AR inhibition does not regulate DNA repair or improve the response to PARP inhibitors. These findings suggest that patients with HR – proficient tumors may not derive significant benefit from this specific combination.”

Title: Lack of synergy between AR – targeted therapies and PARP inhibitors in homologous recombination – proficient prostate cancer

Authors: Nicole A. Traphagen, Esmé Wheeler, Rong Li, Tara Akhshi, Ramya Ravindranathan, Christian Alfieri, Feng Lu, Buraq Ahmed, Alok K. Tewari, Steven P. Balk, Peter S. Nelson, Eva Corey, Henry Long, Alan D. D’Andrea, Xintao Qiu and Myles Brown

Read the article

Yüksel Ürün